Swiss drugmaker Roche Holding AG
Roche said remaining holders of Genentech shares would revive $95 a share. Genentech will cease to be traded on the New York Stock Exchange, Roche said.
After a drawn-out battle, the Swiss drugmaker finally clinched a deal earlier this year for part of the U.S. biotech group it did not own for $46.8 billion.
(Reporting by Lisa Jucca; editing by John Stonestreet)